



Received: 28 February, 2021


Accepted: 18 March, 2021

Published: 19 March, 2021

*Corresponding authors: Omer Sager, Department of Radiation Oncology, University of Health Sciences, Gulhane Medical Faculty, Ankara, Turkey, E-mail: +90 312 304 4683; Fax: +90 312 304 4680; E-mail: omersager@gmail.com

ORCID: <https://orcid.org/0000-0001-7866-2598>

Keywords: Radiation Therapy (RT); Bone metastasis; Soft tissue component; Magnetic Resonance Imaging (MRI)

<https://www.peertechzpublications.com>

Research article

Radiation Therapy (RT) target determination for irradiation of bone metastases with soft tissue component: Impact of multimodality imaging

Omer Sager*, Ferrat Dincoglan, Selcuk Demiral and Murat Beyzadeoglu

Department of Radiation Oncology, University of Health Sciences, Gulhane Medical Faculty, Ankara, Turkey

Abstract

Objective: Management options for bone metastases include surgical interventions, Radiation Therapy (RT), chemotherapy and other systemic and targeted agents. RT as external beam irradiation and by use of stereotactic radiotherapeutic approaches has been utilized for safe and efficacious management of bone metastases. In the context of bone metastases with extraosseous soft tissue mass, the issue of irradiation target definition is a critical component of radiotherapeutic management for successful treatment. Herein, we evaluated target definition for irradiation of bone metastases with soft tissue component by incorporation of multimodality imaging.

Materials and methods: RT target definition for irradiation of bone metastases with soft tissue component was assessed in this study.

Results: Patients receiving palliative irradiation for bone metastases with soft tissue component were assessed for target volume determination. Treatment planning process was performed using the Elekta Precise treatment planning system (Elekta, UK) at our department. Definition of ground truth target volume was performed by the board certified radiation oncologists following meticulous evaluation, colleague peer review, collaboration, and ultimate consensus. Synergy (Elekta, UK) LINAC was used for irradiation. Comparative assessment in our study revealed that ground truth target volume was identical with target volume definition by CT-MR fusion based imaging.

Conclusion: Incorporation of multimodality imaging in target definition of bone metastases with soft tissue component may be utilized for improving the accuracy for precise RT despite the need for further supporting evidence.

Introduction

Bone metastases are among the frequent complications of systemic cancer, and a significant proportion of patients suffer from bone metastases during the course of their malignant disease [1]. Metastases may occur in the form of a single metastatic bone lesion, oligometastatic disease, multiple bone metastases, or visceral metastases with bone metastases. Most frequently affected site includes the vertebrae followed by femur, pelvic bones, ribs, sternum, humerus, and skull. While asymptomatic presentation may be present, affected patients may suffer from a variety of symptoms depending on metastatic disease location, extent and association with

critical neurovascular structures. Skeletal related events due to bone metastases may include pain, compression of nerve roots and the spinal cord, hypercalcemia, myelophthisis, and pathological fractures which could lead to severe consequences and quality of life impairment.

Pain is a very frequent symptom of bone metastases [1,2]. Osteoclasts are thought to play significant role in pathophysiology, and injury of bone and nerve fibers may be responsible for occurrence of pain with both a nociceptive and neuropathic component [3-6].

Management options for bone metastases include surgical interventions, radiation therapy (RT), chemotherapy and



other systemic and targeted agents [4-12]. RT as external beam irradiation and by use of stereotactic radiotherapeutic approaches has been utilized for safe and efficacious management of bone metastases [4-12]. In the context of bone metastases with extraosseous soft tissue mass, the issue of irradiation target definition is a critical component of radiotherapeutic management for successful treatment. Herein, we evaluated target definition for irradiation of bone metastases with soft tissue component by incorporation of multimodality imaging.

Materials and methods

RT target definition for irradiation of bone metastases with soft tissue component was assessed in this study. Comparative analysis of Computed Tomography (CT)-only imaging and CT-magnetic resonance imaging (MRI) based target definition was performed to evaluate the impact of multimodality imaging. Ground truth target volume serving as the reference for actual treatment and comparison purposes was meticulously determined by board certified radiation oncologists following thorough evaluation, colleague peer review, collaboration, and ultimate consensus. All patients included in the study had histopathologically proven cancer diagnosis with radiological verification of bone metastases. Individualized patient assessment was performed to assess lesion size and localization, presenting symptoms, patient preferences, and contemplated outcomes of palliative treatment.

CT-simulator (GE Lightspeed RT, GE Healthcare, Chalfont St. Giles, UK) was utilized for RT simulation for all patients. Planning CT images were acquired and then transferred to the delineation workstation (SimMD, GE, UK) for outlining of target volume and organs at risk (OARs). Either CT-simulation images only or fused CT and MR images were utilized for target volume definition for radiotherapeutic management of bone metastases with soft tissue component. Contoured structure sets were transferred to the Elekta Precise treatment planning system (Elekta, UK) for radiation treatment planning. IGRT was routinely used by incorporating kilovoltage Cone Beam Computed Tomography (kV-CBCT) and X-ray Volumetric Imaging (XVI, Elekta, UK) for setup verification of each patient. Dose fractionation scheme included 30 Gy delivered in 10 fractions over 2 weeks, 20 Gy delivered in 5 fractions over 1 week, or 8 Gy delivered in a single fraction.

Target definition with CT only and with incorporation of CT-MR fusion based imaging was assessed comparatively. Also, patients were also assessed for age, gender, primary cancer diagnosis, location of metastases, and performance status.

Results

Patients receiving palliative irradiation for bone metastases with soft tissue component were assessed for target volume determination based on CT-only imaging and CT-MRI. Patient, tumor, and treatment characteristics are summarized in Table 1.

Table 1: Patient, tumor and treatment characteristics.

Characteristic	Number	%
Number of patients	20	
Median age (range)	63 (51-83) years	
Median KPS (range)	70 (50-100)	
Gender		
Male	11	55
Female	9	45
Primary tumor histology		
Prostate Ca	7	35
Breast Ca	6	30
Lung Ca	5	25
Other	2	10
Involved metastatic region		
hips and pelvis	8	40
lumbar spine	5	25
thoracic spine	4	20
lower limbs	2	10
other	1	10
Dose fractionation scheme		
30 Gy in 10 fractions over 2 weeks	12	60
20 Gy in 5 fractions over 1 week	6	30
8 Gy in 1 fraction	2	10

A total of 20 patients were included in the study. Median age was 63 years (range: 51–83 years). Eleven patients (55%) were male and 9 patients (45%) were female. Involved metastatic region included the hips and pelvis in 8 patients (40%), lumbar spine in 5 patients (25%), thoracic spine in 4 patients (20%), lower limbs in 2 patients (10%), and other location in 1 patient (5%). Median Karnofsky Performance Status was 70 (range: 50–100). Primary diagnosis was prostate cancer, breast cancer, lung cancer, and other for 7 patients (35%), 6 patients (30%), 5 patients (25%), and 2 patients (10%), respectively. Dose fractionation scheme included 30 Gy delivered in 10 fractions over 2 weeks in 12 patients (60%), 20 Gy delivered in 5 fractions over 1 week in 6 patients (30%), or 8 Gy delivered in a single fraction in 2 patients (10%).

Treatment planning process was performed using the Elekta Precise treatment planning system (Elekta, UK) at our department. Sparing of OARs whilst encompassing the target volumes were primary objectives of optimized treatment planning. Definition of ground truth target volume was performed by the board certified radiation oncologists following meticulous evaluation, colleague peer review, collaboration, and ultimate consensus. Synergy (Elekta, UK) LINAC was used for irradiation. Comparative assessment in our study revealed that ground truth target volume was identical with target volume definition by CT-MR fusion based imaging and a 100% overlap was detected between CT-MR fusion based target volume definition and ground truth target volume determination by the board certified radiation oncologists following comprehensive assessment, collaboration, colleague peer review, and ultimate consensus.

Discussion

Bone metastases constitute a very frequent complication of advanced systemic cancer. Pain, hypercalcemia, spinal cord compression and related symptoms are among the potential



consequences which may lead to profound deterioration in affected patients. Among the several promising therapeutic strategies, RT deserves utmost attention as a viable mode of palliative management. There has been extensive study for finding out the optimal radiotherapeutic approach and dose fractionation schemes, however, there seems to be no standard solution to fit all circumstances which indicates the importance of considering individual patient and disease characteristics in the decision making process.

Several factors may be considered in management such as performance status, treatment compliance, life expectancy, primary cancer diagnosis, localization of metastatic lesions, presence of soft tissue involvement, fractures or neurological deficits, and logistical issues. Source availability, staffing, and facility workload may also be taken into account. Clearly, the goal of management should include.

In the era of extremely focused irradiation techniques such as stereotactic body RT (SBRT), it has been more critical to define target volume accurately. From this standpoint, exploiting the advantages of multimodality imaging for precise target definition has been an indispensable component of successful patient management in the millenium era.

There have been several studies exploring the role of multimodality imaging in target definition for radiotherapeutic management of several entities [13-40]. Substantial progress has been achieved in recent years with adoption of adaptive RT strategies and modernized treatment delivery techniques and equipment with incorporation of Intensity Modulated Radiation Therapy (IMRT), Adaptive Radiation Therapy (ART), Breathing Adapted Radiation Therapy (BART), IGRT, automatic segmentation techniques, molecular imaging methods, and stereotactic irradiation approaches [41-75].

Regarding management of bone metastases, use of RT has been addressed for effective palliation [4-12]. With efficacious local and systemic treatment approaches, there have been improvements in survival of patients suffering from metastatic cancer. Longer life expectancy of patients has rendered quality of life a critical aspect of successful management. Contemporary radiotherapeutic strategies increase the importance of precise RT target definition for an improved therapeutic ratio. Within this context, incorporation of multimodality imaging in target definition of bone metastases with soft tissue component may be utilized for improving the accuracy for precise RT. Admittedly, definition of the ground truth target volume for utilization in actual treatment and comparison purposes may be considered as a critical issue prone to variations due to possible interobserver variations. In this study, board certified radiation oncologists have performed definition of ground truth target volume following detailed evaluation, colleague peer review, collaboration, and ultimate consensus to achieve optimal results.

Conclusion

Bone metastases comprise a common complication of systemic cancer. Avoidance of excessive radiation induced toxicity is a critical concern for radiotherapeutic management

of bone metastases. Given the significant workload, there may be differences in practice patterns worldwide regarding the incorporation of image guidance and multimodality imaging techniques. From this aspect, our study may add to the literature with routine utilization of these contemporary strategies in patient management.

In conclusion, incorporation of multimodality imaging in target definition of bone metastases with soft tissue component may be utilized for improving the accuracy for precise RT despite the need for further supporting evidence.

References

1. Brodowicz T, Hadji P, Niepel D, Diel I (2017) Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer. *Cancer Treat Rev* 61: 23-34. [Link: http://bit.ly/38WmKv9](http://bit.ly/38WmKv9)
2. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 12: 6243s-6249s. [Link: http://bit.ly/3cOGZMh](http://bit.ly/3cOGZMh)
3. Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, et al. (2010) Bone cancer pain. *Ann N Y Acad Sci* 1198: 173-181.
4. Mantyh PW (2014) Bone cancer pain: from mechanism to therapy. *Curr Opin Support Palliat Care* 8: 83-90. [Link: http://bit.ly/3eVxQo4](http://bit.ly/3eVxQo4)
5. Maurizi A, Rucci N (2018) The Osteoclast in Bone Metastasis: Player and Target. *Cancers (Basel)* 10: 218. [Link: http://bit.ly/3eRVD8p](http://bit.ly/3eRVD8p)
6. Zajaczkowska R, Kocot-Kępska M, Leppert W, Wordliczek J (2019) Bone Pain in Cancer Patients: Mechanisms and Current Treatment. *Int J Mol Sci* 20: 6047. [Link: http://bit.ly/3s1ryqD](http://bit.ly/3s1ryqD)
7. Selvaggi G, Scagliotti GV (2005) Management of bone metastases in cancer: a review. *Crit Rev Oncol Hematol* 56: 365-378. [Link: http://bit.ly/3c0HT9I](http://bit.ly/3c0HT9I)
8. De Felice F, Piccioli A, Musio D, Tombolini V (2017) The role of radiation therapy in bone metastases management. *Oncotarget* 8: 25691-25699. [Link: http://bit.ly/3ltpIMR](http://bit.ly/3ltpIMR)
9. Lutz S, Berk L, Chang E, Chow E, Hahn C, et al. (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. *Int J Radiat Oncol Biol Phys* 79: 965-976. [Link: http://bit.ly/2NvOIX4](http://bit.ly/2NvOIX4)
10. Moraes FY, Chen X, Yan M, Spratt DE, Redmond K, et al. (2020) Evolving Role of Stereotactic Body Radiation Therapy in the Management of Spine Metastases: Defining Dose and Dose Constraints. *Neurosurg Clin N Am* 31: 167-189. [Link: http://bit.ly/38TndhO](http://bit.ly/38TndhO)
11. Spencer KL, van der Velden JM, Wong E, Seravalli E, Sahgal A, et al. (2019) Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases. *J Natl Cancer Inst* 111: 1023-1032. [Link: http://bit.ly/3s12qAo](http://bit.ly/3s12qAo)
12. De la Pinta C (2020) SBRT in non-spine bone metastases: a literature review. *Med Oncol* 37: 119. [Link: http://bit.ly/3vQNIOK](http://bit.ly/3vQNIOK)
13. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Assessment of posterior fossa target definition by multimodality imaging for patients with medulloblastoma. *J Surg Surgical Res* 7: 037-041.
14. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Evaluation of Changes in Tumor Volume Following Upfront Chemotherapy for Locally Advanced Non Small Cell Lung Cancer (NSCLC). *Glob J Cancer Ther*. 7: 031-034.
15. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2021) Evaluation of Target Definition for Management of Myxoid Liposarcoma (MLS) with Neoadjuvant Radiation Therapy (RT). *Biomed J Sci Tech Res* 33: 26171-26174.



16. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2021) Assessment of Multimodality Imaging for Target Definition of Intracranial Chondrosarcomas. *Canc Therapy Oncol Int J* 18: 555981.
17. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Impact of Multimodality Imaging to Improve Radiation Therapy (RT) Target Volume Definition for Malignant Peripheral Nerve Sheath Tumor (MPNST). *Biomed J Sci Tech Res* 34: 26734-26738.
18. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Treatment Volume Determination for Irradiation of Recurrent Nasopharyngeal Carcinoma with Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6: 18-23.
19. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2021) Multimodality Imaging Based Target Definition of Cervical Lymph Nodes in Precise Limited Field Radiation Therapy (Lfrt) for Nodular Lymphocyte Predominant Hodgkin Lymphoma (Nlph). *ARC Journal of Cancer Science* 6: 06-11.
20. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Target Definition of orbital Embryonal Rhabdomyosarcoma (Rms) by Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6: 12-17.
21. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Assessment of Target Volume Definition for Irradiation of Hemangiopericytomas: An Original Article. *Canc Ther Oncol Int J* 17. [Link: https://bit.ly/3bMfQub](https://bit.ly/3bMfQub)
22. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Evaluation of Radiosurgery Target Volume Definition for Tectal Gliomas with Incorporation of Magnetic Resonance Imaging (MRI): An Original Article. **Biomedical Journal of Scientific & Technical Research (BJSTR)** 27: 20543-20547. [Link: https://bit.ly/3bNk0l0](https://bit.ly/3bNk0l0)
23. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Treatment Volume Determination for Irradiation of chordoma: an Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5: 3-8. [Link: https://bit.ly/3rSbLKE](https://bit.ly/3rSbLKE)
24. Dincoglan F, Beyzadeoglu M, Demiral S, Sager O (2020) Assessment of Treatment Volume Definition for Irradiation of Spinal Ependymomas: an Original Article. *ARC Journal of Cancer Science* 6: 1-6. [Link: https://bit.ly/2Q387zE](https://bit.ly/2Q387zE)
25. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2020) Utility of Multimodality Imaging Based Target Volume Definition for Radiosurgery of Trigeminal Neuralgia: An Original Article. *Biomed J Sci Tech Res* 26: 19728-19732. [Link: https://bit.ly/2OXKAja](https://bit.ly/2OXKAja)
26. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Target Volume Determination for Irradiation of Pilocytic Astrocytomas: An Original Article. *ARC Journal of Cancer Science* 6: 1-5. [Link: https://bit.ly/3rRdSyc](https://bit.ly/3rRdSyc)
27. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2020) Target Volume Definition for Stereotactic Radiosurgery (SRS) Of Cerebral Cavernous Malformations (CCMs). *Canc Therapy Oncol Int J* 15: 555917. [Link: https://bit.ly/3ldxeV6](https://bit.ly/3ldxeV6)
28. Beyzadeoglu M, Dincoglan F, Sager O, Demiral S (2020) Determination of Radiosurgery Treatment Volume for Intracranial Germ Cell Tumors (GCTS). *Asian Journal of Pharmacy, Nursing and Medical Sciences* 8: 18-23. [Link: https://bit.ly/3toPNzn](https://bit.ly/3toPNzn)
29. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Assessment of Target Volume Definition for Radiosurgery of Atypical Meningiomas with Multimodality Imaging. *Journal of Hematology and Oncology Research* 3: 14-21. [Link: https://bit.ly/3eFbEy7](https://bit.ly/3eFbEy7)
30. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Radiosurgery Treatment Volume Determination for Brain Lymphomas with and without Incorporation of Multimodality Imaging. *Journal of Medical Pharmaceutical and Allied Sciences* 9: 2398-2404. [Link: https://bit.ly/3eyrkn0](https://bit.ly/3eyrkn0)
31. Beyzadeoglu M, Dincoglan F, Demiral S, Sager O (2020) Target Volume Determination for Precise Radiation Therapy (RT) of Central Neurocytoma: An Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5: 29-34.
32. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Incorporation of Multimodality Imaging in Radiosurgery Planning for Craniopharyngiomas: An Original Article. *SAJ Cancer Sci* 6: 103. [Link: https://bit.ly/2NiFkpL](https://bit.ly/2NiFkpL)
33. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Evaluation of the Impact of Magnetic Resonance Imaging (MRI) on Gross Tumor Volume (GTV) Definition for Radiation Treatment Planning (RTP) of Inoperable High Grade Gliomas (HGGs). *Concepts in Magnetic Resonance Part A* 2019: 4282754. [Link: https://bit.ly/3qK77Nn](https://bit.ly/3qK77Nn)
34. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) Based Radiosurgery Treatment Planning for Pituitary Adenomas. *Canc Therapy Oncol Int J* 13: 555857. [Link: https://bit.ly/3qKvFPR](https://bit.ly/3qKvFPR)
35. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of target definition based on Multimodality imaging for radiosurgical Management of glomus jugulare tumors (GJTs). *Canc Therapy Oncol Int J* 15: 555909. [Link: https://bit.ly/3vp4hB2](https://bit.ly/3vp4hB2)
36. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Utility of Magnetic Resonance Imaging (Imaging) in Target Volume Definition for Radiosurgery of Acoustic Neuromas. *Int J Cancer Clin Res* 6: 119. [Link: https://bit.ly/3bMhr3j](https://bit.ly/3bMhr3j)
37. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2019) Evaluation of Radiosurgery Target Volume Determination for Meningiomas Based on Computed Tomography (CT) And Magnetic Resonance Imaging (MRI). *Cancer Sci Res Open Access* 5: 1-4. [Link: https://bit.ly/3vp4hkw](https://bit.ly/3vp4hkw)
38. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Multimodality Imaging for Radiosurgical Management of Arteriovenous Malformations. *Asian Journal of Pharmacy, Nursing and Medical Sciences* 7: 7-12. [Link: https://bit.ly/3cwnFmX](https://bit.ly/3cwnFmX)
39. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S (2019) Evaluation of Target Definition for Stereotactic Reirradiation of Recurrent Glioblastoma. *Arch Can Res* 7: 3. [Link: https://bit.ly/20pxR90](https://bit.ly/20pxR90)
40. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2018) Evaluation of Target Volume Determination for Single Session Stereotactic Radiosurgery (SRS) of Brain Metastases. *Canc Therapy Oncol Int J* 12: 555848. [Link: https://bit.ly/2MXRS1K](https://bit.ly/2MXRS1K)
41. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Omission of Radiation Therapy (RT) for Metaplastic Breast Cancer (MBC): A Review Article. *International Journal of Research Studies in Medical and Health Sciences* 6: 10-15.
42. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2020) Adaptive radiation therapy of breast cancer by repeated imaging during irradiation. *World J Radiol* 12: 68-75. [Link: https://bit.ly/3bKVSzT](https://bit.ly/3bKVSzT)
43. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Breathing adapted radiation therapy for leukemia relapse in the breast: A case report. *World J Clin Oncol* 10: 369-374. [Link: https://bit.ly/3qNJsLS](https://bit.ly/3qNJsLS)
44. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective. *Curr Radiopharm* 12: 4-10. [Link: https://bit.ly/3bKW7eh](https://bit.ly/3bKW7eh)
45. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2018) Evaluation of adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma. *Jpn J Radiol* 36: 401-406. [Link: https://bit.ly/3bOpQmV](https://bit.ly/3bOpQmV)
46. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2017) Splenic Irradiation: A Concise Review of the Literature. *J App Hem BI Tran* 1: 101. [Link: https://bit.ly/3eBmtkP](https://bit.ly/3eBmtkP)



47. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2015) Adaptive splenic radiotherapy for symptomatic splenomegaly management in myeloproliferative disorders. *Tumori* 101: 84-90. [Link: https://bit.ly/20Ae0DT](https://bit.ly/20Ae0DT)
48. Özsvaşa EE, Telatar Z, Dirican B, Sağır Ö, Beyzadeoğlu M (2014) Automatic segmentation of anatomical structures from CT scans of thorax for RTP. *Comput Math Methods Med* 2014: 472890. [Link: https://bit.ly/3q0sJc3](https://bit.ly/3q0sJc3)
49. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Kahya YE, et al. (2013) Dosimetric evaluation of critical organs at risk in mastectomized left-sided breast cancer radiotherapy using breath-hold technique. *Tumori* 99: 76-82. [Link: https://bit.ly/20oOmSM](https://bit.ly/20oOmSM)
50. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) Evaluation of active breathing control-moderate deep inspiration breath-hold in definitive non-small cell lung cancer radiotherapy. *Neoplasma* 59: 333-340. [Link: http://bit.ly/3cVtnNh](http://bit.ly/3cVtnNh)
51. Sager Ö, Dinçoglan F, Gamsiz H, Demiral S, Uysal B, et al. (2012) Evaluation of the impact of integrated [18f]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging on staging and radiotherapy treatment volume definition of nonsmall cell lung cancer. *Gulhane Med J* 54: 220-227. [Link: https://bit.ly/3htqTt5](https://bit.ly/3htqTt5)
52. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) The Role of Active Breathing Control-Moderate Deep Inspiration Breath-Hold (ABC-mDIBH) Usage in non-Mastectomized Left-sided Breast Cancer Radiotherapy: A Dosimetric Evaluation. *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi* 22: 147-155. [Link: http://bit.ly/3bMn7dF](http://bit.ly/3bMn7dF)
53. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Gamsiz H, et al. (2020) Multimodality management of cavernous sinus meningiomas with less extensive surgery followed by subsequent irradiation: Implications for an improved toxicity profile. *J Surg Surgical Res* 6: 056-061. [Link: https://bit.ly/3toiKvl](https://bit.ly/3toiKvl)
54. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Uysal B, et al. (2020) A Concise Review of Irradiation for Temporal Bone Chemodectomas (TBC). *Arch Otolaryngol Rhinol* 6: 016-020. [Link: https://bit.ly/3cymTWr](https://bit.ly/3cymTWr)
55. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, Uysal B, et al. (2020) Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated Stereotactic Radiotherapy (FSRT) for Vestibular Schwannoma (VS). *J Surg Surgical Res* 6: 062-066. [Link: https://bit.ly/3qVHOs1](https://bit.ly/3qVHOs1)
56. Dincoglan F, Sager O, Demiral S, Gamsiz H, Uysal B, et al. (2019) Fractionated stereotactic radiosurgery for locally recurrent brain metastases after failed stereotactic radiosurgery. *Indian J Cancer* 56: 151-156. [Link: https://bit.ly/3tkGss6](https://bit.ly/3tkGss6)
57. Dincoglan F, Sager O, Uysal B, Demiral S, Gamsiz H, et al. (2019) Evaluation of hypofractionated stereotactic radiotherapy (HFSRT) to the resection cavity after surgical resection of brain metastases: A single center experience. *Indian J Cancer* 56: 202-206. [Link: https://bit.ly/38EOeVM](https://bit.ly/38EOeVM)
58. Demiral S, Dincoglan F, Sager O, Uysal B, Gamsiz H, et al. (2018) Contemporary Management of Meningiomas with Radiosurgery. *Int J Radiol Imaging Technol* 80: 187-190. [Link: https://bit.ly/3rJwiRw](https://bit.ly/3rJwiRw)
59. Dincoglan F, Sager O, Demiral S, Uysal B, Gamsiz H, et al. (2017) Radiosurgery for recurrent glioblastoma: A review article. *Neurol Disord Therap* 1: 1-5. [Link: https://bit.ly/30JZT0Q](https://bit.ly/30JZT0Q)
60. Demiral S, Dincoglan F, Sager O, Gamsiz H, Uysal B, et al. (2016) Hypofractionated stereotactic radiotherapy (HFSRT) for who grade I anterior clinoid meningiomas (ACM). *Jpn J Radiol* 34: 730-737. [Link: https://bit.ly/30FFBpK](https://bit.ly/30FFBpK)
61. Gamsiz H, Beyzadeoglu M, Sager O, Demiral S, Dincoglan F, et al. (2015) Evaluation of stereotactic body radiation therapy in the management of adrenal metastases from non-small cell lung cancer. *Tumori* 101: 98-103. [Link: https://bit.ly/3tkGpNa](https://bit.ly/3tkGpNa)
62. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Gamsiz H, et al. (2015) Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. *Tumori* 101: 179-184. [Link: https://bit.ly/3eDf4BN](https://bit.ly/3eDf4BN)
63. Sager O, Dincoglan F, Beyzadeoglu M (2015) Stereotactic radiosurgery of glomus jugulare tumors: Current concepts, recent advances and future perspectives. *CNS Oncol* 4: 105-114. [Link: https://bit.ly/3lh1FjT](https://bit.ly/3lh1FjT)
64. Gamsiz H, Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, et al. (2014) Management of pulmonary oligometastases by stereotactic body radiotherapy. *Tumori* 100: 179-183. [Link: https://bit.ly/2Q7uCDH](https://bit.ly/2Q7uCDH)
65. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of linear accelerator (linac)-based stereotactic radiosurgery (srs) for the treatment of craniopharyngiomas. *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi* 24: 123-129. [Link: https://bit.ly/3vr4Dql](https://bit.ly/3vr4Dql)
66. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of linear accelerator (linac)-based stereotactic radiosurgery (srs) for the treatment of craniopharyngiomas. *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi* 24: 123-129. [Link: https://bit.ly/3vr4Dql](https://bit.ly/3vr4Dql)
67. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2014) Management of patients with ≥ 4 brain metastases using stereotactic radiosurgery boost after whole brain irradiation. *Tumori* 100: 302-306. [Link: https://bit.ly/3rOh6CN](https://bit.ly/3rOh6CN)
68. Sager O, Beyzadeoglu M, Dincoglan F, Uysal B, Gamsiz H, et al. (2014) Evaluation of linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) for cerebral cavernous malformations: A 15-year single-center experience. *Ann Saudi Med* 34: 54-58. [Link: https://bit.ly/3rPpuBM](https://bit.ly/3rPpuBM)
69. Sager O, Beyzadeoglu M, Dincoglan F, Gamsiz H, Demiral S, et al. (2014) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of glomus jugulare tumors. *Tumori* 100: 184-188. [Link: https://bit.ly/38F16eL](https://bit.ly/38F16eL)
70. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2013) Management of vestibular schwannomas with linear accelerator-based stereotactic radiosurgery: a single center experience. *Tumori* 99: 617-622. [Link: https://bit.ly/3bMgoAf](https://bit.ly/3bMgoAf)
71. Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, et al. (2013) Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. *Neoplasma* 60: 322-327. [Link: https://bit.ly/20Re4iD](https://bit.ly/20Re4iD)
72. Dincoglan F, Beyzadeoglu M, Sager O, Uysal B, Demiral S, et al. (2013) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of meningiomas: A single center experience. *J Buon* 18: 717-722. [Link: https://bit.ly/3litoRa](https://bit.ly/3litoRa)
73. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2012) Stereotactic radiosurgery for intracranial tumors: A single center experience. *Gulhane Med J* 54: 190-198. [Link: https://bit.ly/3cYmv1J](https://bit.ly/3cYmv1J)
74. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Sirin S et al. (2012) Image-guided positioning in intracranial non-invasive stereotactic radiosurgery for the treatment of brain metastasis. *Tumori* 98: 630-635. [Link: http://bit.ly/2B0tOZA](http://bit.ly/2B0tOZA)
75. Sirin S, Oysul K, Surenkok S, Sager O, Dincoglan F, et al. (2011) Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience. *Vojnosanit Pregl* 68: 961-966. [Link: http://bit.ly/3hqfBGb](http://bit.ly/3hqfBGb)

Copyright: © 2021 Sager O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Radiation Therapy (RT) target determination for irradiation of bone metastases with soft tissue component: Impact of multimodality imaging. *J Surg Surgical Res* 7(1): 042-046. DOI: <https://dx.doi.org/10.17352/2455-2968.000134>